Preventing HIV-associated tuberculosis with antiretroviral therapy: Shut the stable door early!

International Journal of Tuberculosis and Lung Disease

Volumn 19, Issue 1, 2015, Pages 3-4

  Lawn, Stephen D ^a,b  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRAL THERAPY; BACTERIAL TRANSMISSION; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL (TOPIC); DRUG RESISTANCE; DRUG THERAPY; EDITORIAL; HIV ASSOCIATED TUBERCULOSIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; RISK REDUCTION; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; FEMALE; HIV INFECTIONS; MALE; STATISTICS AND NUMERICAL DATA; TIME TO TREATMENT;

ANTIRETROVIRUS AGENT;

ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HUMANS; MALE; TIME-TO-TREATMENT; TUBERCULOSIS;

EID: 84918785944     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.14.0884     Document Type: Editorial

References (10)

1. Lawn S D, Wood R, De Cock K M, Kranzer K, Lewis J J, Churchyard G J. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis 2010;10:489-498.
2. Suthar A B, Lawn S D, Del Amo J, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLOS MED 2012;9:e1001270.
3. Lawn S D, Harries A D, Williams B G, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011;15:571-581.
4. Middelkoop K, Bekker L G, Myer L, et al. Antiretroviral therapy and TB notification rates in a high HIV prevalence South African community. J Acquir Immune Defic Syndr 2011;56:263-269.
5. Kanyerere H, Mganga A, Harries A D, et al. Decline in national tuberculosis notifications with national scale-up of antiretroviral therapy in Malawi. Public Health Action 2014;4:113-115.
6. Lawn SD, Myer L, Bekker LG, Wood R. Burdenof tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006;20:1605-1612.
7. Collins S E, Jean Juste M A, Koenig S P, et al. CD4 deficit and tuberculosis risk persist with delayed antiretroviral therapy: 5-year data from CIPRA HT-001. Int J Tuberc Lung Dis 2015;19:50-57.
8. Lawn S D, Myer L, Edwards D, Bekker L G, Wood R. Shortterm and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009;23:1717-1725.
9. Lawn S D, Bekker L G, Wood R. How effectively does HAART restore immune responses to Mycobacterium tuberculosis? Implications for tuberculosis control. AIDS 2005;19:1113-1124.
10. Cohen M S, Chen Y Q, McCauley M, et al. Preventionof HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011;365:493-505.